QY 401
Alternative Names: QY-401Latest Information Update: 29 Jun 2022
At a glance
- Originator E-nitiate Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory tract disorders
Most Recent Events
- 29 Jun 2022 QY 401 is available for licensing as of 29 Jun 2022. http://www.enitiatebio.com/en.php/cooperation/
- 10 Dec 2021 E-nitiate Biopharmaceuticals has global patents for QY 401 before December 2021
- 29 Oct 2021 Preclinical trials in Respiratory tract disorders in China, USA (unspecified route) before October 2021